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Summary 
Cytotoxic T cells (CTL) represent the major defense mechanism against he spread of virus in- 
fection. It is believed that the pore-forming protein, perforin, facilitates the entry of a series of 
serine proteases (particularly granzyme B) into the target cell which ultimately leads to DNA 
fragmentation and apoptosis. We demonstrate here that during CTL-mediated cytolysis the 
catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), an enzyme implicated in the 
repair of double strand breaks in DNA, is specifically cleaved by an interleukin (IL)-l[3-con- 
verting enzyme (ICE)-like protease. A serine protease inhibitor, 3,4-dichloroisocoumarin 
(DCI), which is known to block granzyme B activity, inhibited CTL-induced apoptosis and 
prevented the degradation of DNA-PKcs in cells but failed to prevent he degradation of puri- 
fied DNA-PKcs by CTL extracts. However, Tyr-Val-Ala-Asp-CH2C1 (YVAD-CMK) and 
other cysteine protease inhibitors prevented the degradation of purified DNA-PKcs by CTL 
extracts. Furthemmre, incubation of DNA-PKcs with granzyme B did not produce the same 
cleavage pattern observed in cells undergoing apoptosis and when this substrate was incubated 
with either CTL extracts or the ICE-like protease, CPP32. Sequence analysis revealed that the 
cleavage site in DNA-PKcs during CTL killing was the same as that when this substrate was 
exposed to CPP32. This study demonstrates for the first time that the cleavage of DNA-PKcs 
in this intact cell system is exclusively due to an ICE-like protease. 
W~n ile CTLs can kill their targets by several mecha- isms, cell death and DNA fragmentation may be 
achieved by a combination of the actions of perforin and 
serine proteases (granzymes) present in their lysosome-like 
cytoplasmic granules (1, 2). Granule exocytosis delivers per- 
forin, a pore-forming protein to the surface of the target 
cell, causing membrane damage and ultimately cell death 
(3). Perforin alone does not cause DNA fragmentation or
apoptosis (4), however the granzymes, particularly granzyme 
B (fragmentin-2), have been implicated in these processes 
(3, 5-7). Granzyme B is only expressed athigh levels in ac- 
tivated CTL, lymphokine-activated killers (LAK), and nat- 
ural killer (NK) cells (7-9). Inhibition of NK cell-induced 
cytolysis by inhibitors of serine proteases, uch as isocou- 
matin, provides evidence that granzyme B or a related pro- 
tease participates in the apoptotic process (10, 11). Further- 
more, the generation of mice with a homozygous null 
mutation in the granzyme B gene demonstrates that this 
enzyme plays a critical, non-redundant role in the rapid 
induction of DNA fragmentation and apoptosis in CTL 
targets (9). Two recent reports provide evidence that this 
role is probably indirect and is achieved by cleaving and ac- 
tivating an IL-l~-converting enzyme (ICE)i-like protease 
(12, 13). 
Although the degradation of DNA into oligonncleoso- 
I Abbreviations u ed in this paper: DCI, 3,4-dichloroisocoumarin; ICE, in- 
terleukin-1 B-converting enzyme; PARK, poly (ADP-ribose) polymerase; 
TLCK, tosyl-l-lysine chloromethyl ketone. 
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mal sized fragments has been shown to be a characteristic of
apoptosis for some time (14), and while a number of candi- 
date endonucleases have been reported (15-18), the factor 
responsible for DNA fragmentation remains elusive. An in- 
triguing observation stems from the report that CTL gran- 
ule proteinases can induce the internal disintegration path- 
way in target cells (I 9, 20). One such proteinase, granzyme 
B, when it gains access to the target cell through perforin, 
causes fragmentation i DNA.  The identity of  the target 
proteins of  granzyme B that trigger apoptosis remains un- 
clear, but a recent report has shown that purified enzyme 
cleaves and activates CPP32 (12), the precursor of an ICE- 
like protease that cleaves Poly (ADP-ribose) polymerase 
(PARP) during apoptosis (21-24). PAILP is one of a few 
key substrates degraded uring the process ofapoptosis (23, 
25), which additionally include nuclear lamin (26, 27), U1-  
70 small nuclear ribonucleoprotein (28), fodrin (29), actin 
(30), topoisomerase 1 (25, 31), and DNA-PKcs (32, 33). In 
this study, we demonstrate that the catalytic subunit of  
DNA-dependent  kinase is specifically cleaved uring CTL-  
mediated cytolysis. Furthermore, we show that granzyme B
or another serine protease activates an ICE-l ike protease to 
cleave DNA-PKcs during this process. 
Materials and Methods 
Reagents. Leupeptin, E-64, pepstatin, tosyl-L-lysine chlorom- 
ethyl ketone (TLCK), tosyl-L-phenylalanine chloromethyl ke- 
tone (TPCK), and 3,4-dichloroisocoumarin (DCI), were ob- 
tained from Boehringer Mannheim (Indainapolis, IN). PMSF, 
iodoacetamide, and N-ethylmaleimide were from Sigma Chem. 
Co. (St. Louis, MO), and Tyr-Val-Ala-Asp-CH2C1 (YVAD-CMK) 
from Bachem (Torrance, CA). Protease inhibitor stock solutions 
were made up as follows: PMSF, 0.2 M in methanol; eupeptin, 1
mg/ml in water; pepstatin, 1 mg/ml in methanol; E-64, 10 mg/ml 
in a mixture of ethanol/water; TLCK, 20 mM in methanol; 
TPCK, 40 mM in ethanol; DCI, 50 mM in DMSO; iodoaceta- 
mide, 100 mM in DMSO; N-ethylmaleimide, 100 mM in DMSO, 
and YVAD-CMK, 2 mM in DMSO. 
The following antibodies were used for immunoblotting of
DNA-PKcs. Ab-SLY, a polyclonal antibody raised against amino 
acid region 1550-1840 of DNA-PKcs; DPK1, a polyclonal anti- 
body raised against amino acid region 2018-2136; Ab9607, a 
polyclonal antibody against amino acid region 2790-3065; Ab42- 
47, a monoclonal antibody recognizing the kinase (exact se- 
quence undefined) domain and Ab-FLA an antibody against he 
whole molecule. A mouse polyclonal antibody that detects both 
Ku70 and 80 was also used (34). 
Induction of Apoptosis During Cytotoxic T Cell Killing. The CTL 
clone was generated as described previously (35). Clone LC13 is 
HLA B8-restricted and it recognizes the epitope FLRGRAYGL. 
In this system CTLs act as both effector cells and target cells (35). 
For CTL-mediated cytolysis peptide FLRGRAYGL was added 
to U-shaped microtiter wells (10 raM) containing 10 s cells and 
incubated for 15 rain at 37~ before centrifugation at200 g and 
further incubation at 37~ for the times indicated in individual 
experiments, before harvesting and extraction of proteins. An ir- 
relevant peptide EENLLDFVP, E (10 raM) was used as a control. 
An HLA B44-restricted clone, but not clone LC13 recognizes 
this EBV epitope (35). 
Western Blot Analysis. After the various treatments, cells were 
pelleted at 200 g, followed by two washes in ice-cold PBS, pH 
7.2, and were then resuspended in extraction buffer (50 mM 
Tris-HCI, 150 mM NaCI, 2 mM EDTA, 2 mM EGTA, 25 mM 
NaF, and 25 mM [3-glycerolphosphate, pH 7.5), 0.2% Triton 
X-100, 0.3% NP-40, 0.1 mM sodium vanadate, 0.1 mM PMSF, 
leupeptin (5 mg/ml), aprotinin (5 mg/ml), and left on ice for 10 
rain. After centrifugation at 10,000 g for 10 min at 4~ the su- 
pernatant was collected and cell extract was assayed for protein 
using the Bio-lLad microassay (Bio-ILad Labs., Richmond, CA). 
One-fifth of a volume of 5 times concentrated sample buffer 
(0.25 M Tris-HCI, pH 6.8, 0.4 M DTT, 5% SDS, 0.5% Brom- 
phenol Blue, 50% glycerol) was added to each sample and boiled 
for 5 min before storage at -80~ Electrophoresis was per- 
formed on 20 Ixg of protein sample on 8% SDS-PAGE. Proteins 
were then transferred to PVDF membranes and immunoblotting 
was performed with the appropriate antibody using an ECL kit 
(Amersham Corp., Arlington Heights, IL). In some cases, blots 
were reprobed with different antibodies after stripping in 62.5 
mM Tris, 100 mM 2-[3-mercaptoethanol/2% SDS, pH 6.7. 
DNA-PKActivity Assay. Whole cell extracts were prepared 
from CTL cells treated with FLtLGRAYGL epitope according to 
procedures described previously (36). DNA-PK activity was as- 
sayed with a synthetic peptide corresponding to the NHz-termi- 
nal region of human p53 gene product (PESQEAFADLWKK) at 
0.25 mM as described previously (36). Each sample was also as- 
sayed in the presence of non-substrate p ptide EPPLSEQFADL- 
WKK. Incorporation of phosphate into this peptide was less than 
5% of that for the substrate peptide, and values were subtracted 
from the appropriate samples. 
In vitro, DNA-PK Cleavage by Granzyme B and CPP32 Proteases. 
DNA-PKcs was purified as described previously (34). Ku proteins 
were also prepared as part of this protocol. Purified granzyme B
was used in the cleavage studies (37, 38). This enzyme was shown 
to be free of other granzyme activities uch as tryptase (grA) and 
Met-ase. The recombinant foml of the ICE-like protease CPP32 
was prepared as a bacterial lysate as described previously (39). For 
cleavage of DNA-PKcs 10 ng of purified granzyme B was incu- 
bated with 0.2 Ixg of purified protein in a 20-~zl reaction volume 
containing 10 mM Hepes, pH 7.4, 0.1 mM EDTA, and 5 mM 
DTT for 2 h at 37~ Incubations also contained sonicated calf 
thymus DNA (0.2 p,g). The reactions were terminated by addi- 
tion of 5 ml of loading buffer (5 times concentrated) followed by 
separation on 8% SDS-PAGE and immunoblotting was carried 
out with DPK1 antibody. Ku (0.2 ~g) was incubated with 10 ng 
of purified granzyme B as described for DNA-PKcs. Incubations 
also contained DNA-PKcs (0.2 Ixg) and sonicated calf thymus 
DNA (0.2 p~g). Immunoblotting was carried out with polyclonal 
antibody against Ku (34). For cleavage with CPP32, 2 btl of bac- 
terial lysate containing the recombinant protein was incubated 
with DNA-PKcs (0.2 Ixg), Ku (0.2 Ixg), and sonicated calf thy- 
nms DNA (0.2 Ixg), in a 20-txl reaction volume containing 25 
mM Hepes, pH 7.5, 5 mM EDTA, 5 mM DTT, and 0.1% 3-[(3- 
cholamidopropyl) dimethylamino]-l-propanesulfonate (CHAPS) 
for 20 min at 37~ 
Preparation of Extracts for DNA-PK Cleavage In Vitro. Cell ex- 
tracts were prepared from CTL clone LC13 cells treated with 
specific etoposide FLRGRAYGL 4 h post-treatment. Cells were 
pelleted at 200 g, followed by two washes in ice-cold PBS, pH 
7.2, and then lysed by sonication in lysis buffer containing 25 
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mM Hepes, pH 7.5, 5 mM EDTA, 2 mM DTT, 0.1% CHAPS, 
and 1 mM PMSF, 2 mg/ml each of aprotinin, leupeptin, a d 
pepstatin. The lysates were centrifuged at 16,000 g for 10 min, 
and the supernatants collected and stored at -20~ until re- 
quired. For cleavage of DNA-PKcs, extracts (4 lag of total pro- 
tein) were preincubated with either leupeptin (210 raM), PMSF 
(1 mM), YVAD-CMK (10 raM), N-ethylmaleimide (5 mM), or 
iodoacetamide (5 mM) for 30 min at 37~ before addition of 
DNA-PKcs (0.2 Ixg) and Ku (0.2 lag) and sonicated calf thymus 
DNA (0.2 }*g) and then incubated for a further 1 h at 37~ in a 
20-ml reaction volume before separation o  8% SDS-PAGE and 
immunoblotting was carried out with DPK1 antibody. 
Microsequencing. Purified DNA-PKcs was digested with either 
CPP32 or extracts from cells undergoing apoptosis as described 
above. Fragments were separated by 8% SDS-PAGE followed by 
transfer to PVDF membranes. The 150- and 120-kD fragments 
generated by DNA-PKcs cleavage after digestion with CPP32 
and the 150-kD fragment generated by igestion of DNA-PKcs 
with cell extracts from CTL clone CL13 cells were sequenced us- 
ing an 473A Gas Phase quencer (Applied Biosystems, Inc., Fos- 
ter City, CA). 
Results  and D iscuss ion  
We have recently shown that the catalytic subunit 
(DNA-PKcs) of DNA-dependent protein kinase (DNA- 
PK) is preferentially degraded in Burkitt's lymphoma nd 
other cell types undergoing apoptosis (32). The DNA-  
binding component of this enzyme, Ku, remained intact 
and inhibitor and in vitro studies implicated the ICE-like 
protease CPP32 in the degradation of DNA-PKcs. Mem- 
bers of the ICE-like family of proteases require the pres- 
ence of an Asp residue at the P1 position for cleavage (22), 
a property shared with the cytotoxic T cell-specific pro- 
tease granzyme B making it unique among serine proteases 
(1). Since granzyme B is necessary for the induction of 
DNA fragmentation and apoptosis in CTL-mediated kill- 
ing it was possible that DNA-PKcs might be a direct target 
for this enzyme or it could involve the activation of an 
ICE-like protease such as CPP32 to cleave DNA-PKcs. To 
address this question we mployed Epstein-Barr Virus-spe- 
cific CTL (clone LC13) which we have demonstrated pre- 
viously to be effective targets for their own lysis when in- 
cubated in the presence of a specific epitope but not in the 
presence of irrelevant epitopes (35). The results in Fig. 1 A 
demonstrate hat when CTL clone LC13 is incubated with 
cognate peptide FLRGRAYGL a time-dependent degra- 
dation of DNA-PKcs to a 240-kD fragment is observed 
when immunoblotting is carried out with antibody DPK1 
prepared against amino acid region 2018-2136 of the pro- 
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Figure 1. (A) Time course of cleavage ofDNA-PKcs after exposure of 
Epstein Ban- Virus-specific CTL clone LC13 to specific peptide. The 
CTL clone was generated as described previously (35). Extracts were pre- 
pared as described in Materials and Methods, electrophoresed on 8% 
SDS-PAGE and immunoblotting wasperformed with DPK1 antibody 
which recognizes a peptide containing amino acids 2018-2136 in DNA- 
PKcs using an ECL kit (Amersham). (B) Time course in the presence ofirrelevant peptide. Clone LC13 was also incubated inthe presence ofan irrele- 
vant peptide (EENLLDFVRE, 10 mM). An HLA B44-restricted clone but not clone LC13 recognizes this EBV epitope (35). (C) Lack of degradation f 
Ku70 and Ku80, the DNA-binding component of DNA-PK, during apoptosis inCTL clone LC 13 in the presence ofspecific peptide with time after ex- 
posure. (D) Time course ofDNA-PK activity in CTL clone LC13 incubated with specific epitope (FLRGRAYGL). DNA-PK activity was assayed with 
a synthetic peptide (PESQEAFADLWKK) substrate asdescribed previously (47). Each sample was also assayed inthe presence ofnon-substrate peptide EPP- 
LSEQFADLWKK. 
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Figure 2. Effect ofprotease inhibitors on 1)NA-PKcs cleavage inCTL 
clone LC13 undergoing apoptosis. (;ells were exposed to the following 
inhibitors pepstatin (3.6 raM), leupeptin (210 raM), E-64 (50 raM), 
PMSF (I raM), I)C1 (200 raM), and TPCK (200 raM) fbr 30 rain before 
exposure to specific peptide for I5 rain followed by harvesting 4 h later. 
I)NA-PKcs was detected with I)PK1 antibody. 
tein (40). After 4 h incubation with FLRGR.AYGL ~60% 
degradation of  DNA-PKcs is observed which agrees well 
with the extent of  specific lysis at this time point as mea- 
sured by chromium release (35). The size of  this fragment is 
comparable to that occurring in other cell types exposed to 
a variety of  agents that cause apoptosis (32). Exposure of 
CTL clone LC13 to a non-specific epitope (EENLLD- 
FVIR.E) which fails to elicit lysis in this clone did not cause 
any degradation of  DNA-PKcs up to 8 h incubation (Fig. 1 
/3). Under these conditions there was no evidence for deg- 
radation of  either Ku70 or Ku80, the DNA-binding com- 
ponent of DNA-PK (Fig. 1 C). 
As expected, the activity of  DNA-PK in CTL clone 
LC 13 was markedly reduced with time after the addition of  
cognate epitope FLIR.GRAYGL, being reduced to 31% of 
that in untreated cells after 4 h (Fig. 1 D). This reduction in 
activity paralleled the degradation of I)NA-PKcs and is also 
in agreement with data observed in etoposide treated Bur- 
kitt's lymphoma cells (32). In an attempt o identify the na- 
ture of  the protease involved in DNA-PKcs degradation, 
we employed a number ofprotease inhibitors. TPCK (cys- 
teine and serine protease inhibitor) and DC1 (serine pro- 
tease inhibitor) prevented apoptosis during CTL killing (re- 
sults not shown), and were also capable of  inhibiting the 
degradation of DNA-PKcs, while other inhibitors such as 
leupeptin, pepstatin, PMSF, and E64 failed to do so (Fig. 
2). It was not possible to use iodoacetamide and _NLethyl- 
maleimide, two cysteine protease inhibitors, with whole 
cells because of their toxicity. These results suggested that a 
serine type protease, such as granzyme B, might be respon- 
sible for the degradation of  DNA-PKcs (41). To substanti- 
ate this further, purified DNA-PKcs was exposed to 
granzyme B. In the presence of Ku, DNA-PKcs was de- 
graded to a fragment of  similar size (240 kD) to that ob- 
served in CTL undergoing apoptosis, as detected with 
DPK1 antibody (Fig. 3 A, lane 3). When Ku was excluded 
from the incubation mix cleavage was less effective with an 
intermediate-sized fragment being evident (Fig. 3 A, lane 
2). Use of an antibody specific for Ku (34) demonstrated that 
there was some cleavage of both Ku70 and Ku80 by 
granzyme B under these conditions (Fig. 3 B, lane 2). No 
degradation of Ku was observed in CTL (Fig. 3 B, lane 3) 
or Burkitt's cells (Fig. 3 B, lane 4) undergoing apoptosis or 
when the purified complex was exposed to CPP32 (lane 5). 
Use of  an antibody that detected all regions of  DNA-  
PKcs (Ab-FLA) also revealed only a single degradation 
fragment of  240 kD after incubation of  DNA-PKcs with 
granzyme B (Fig. 3 C, lane 2). Furthermore, the salne 
cleavage pattern was observed when purified DNA-PKcs 
was incubated with granzyme B at 10 ng over the time 
range 0-3 h (Fig. 3 D; lanes I-6) or when purified DNA-  
PKcs was incubated with granzyme B over the dose range 
0-20 ng for a period of  2 11 (Fig. 3 E; lanes 1-6). Use of  
other antibodies pecific for different regions of  DNA-PKcs 
also failed to detect fragments other than the 240-kD flag- 
merit (results not shown). When Ab-FLA was used to de- 
tect DNA-PKcs in extracts from CTL undergoing apopto- 
sis two fragments o f~240 and 150 kD were observed (Fig. 
3 C, lane 3). This pattern was similar to that observed with 
extracts from Burkitt's lymphoma cells undergoing apopto- 
sis induced by etoposide (Fig. 3 C, lane 4). The ICE-like 
protease CPP32, when incubated with purified 1)NA- 
PKcs, also produced fragments of  240 and 150 kD and an 
additional strong band was observed at 12(1 kD (Fig. 3 C, 
lane 5). It was not possible to detect the 120-kD band m 
either the CTL or Burkitt's cell lanes under these condi- 
tions. However, we have previously shown that a weaker 
120-kD band is produced uring apoptosis in Burkitt's cells 
(32). To further distinguish between a role for granzyme B
or an ICE-like protease in this process, extracts were pre- 
pared from CTL exposed to specific peptide for 4 h. As ob- 
served in cells undergoing apoptosis, these extracts also de- 
graded DNA-PKcs to a 240-kD fragment as detected with 
DPK1 antibody (Fig. 4, lane 2). YVAD-chloromethylke- 
tone (CMK), a specific inhibitor of  ICE-like proteases, io- 
doacetamide and N--ethylmaleinlide, cysteine protease in-
hibitors, prevented the degradation f DNA-PKcs by CTL 
extracts (Fig. 4, lanes 5-7, respectively). Neither DC1 nor 
TPCK were able to prevent he degradation of l )NA-PKcs 
by CTL extracts (Fig. 4, lanes 8 and 9, respectively), in 
contrast o the results obtained in whole cells where both 
inhibitors were effective in preventing DNA-PKcs degra- 
dation and onset of  apoptosis (Fig. 2). These data suggest 
that DNA-PKcs is a direct target for an ICE-like protease 
in CTL-mediated cytolysis and that granzyme B partici- 
pates in the process further upstream, possibly activating 
the ICE-like protease. 
We have previously shown that both extracts from Bur- 
kitt's lymphoma cells undergoing etoposide-induced apop- 
tosis and CPP32 incubated with DNA-PKcs gave rise to 
150- and 120-kD fragments (32). Furthermore, NH,-ter-  
minal sequencing revealed that the site of  cleavage that 
generated the 150-kD fragment was DEVDSN (amino ac- 
ids 2709-2713) in both cases. The 120-kD fragment is pro- 
duced from within the 150-kD fragment by cleavage at 
DWVD,I,G (amino acids 2979-2983). Both sequence mo- 
tifs would be expected to be recognized by ICE-like pro- 
teases (22, 42). Microsequencing of the 150-kD fragment 
generated from incubation of  DNA-PKcs with CTL ex- 
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Figure 3. (A) Cleavage of purified DNA-PKcs by granzyme B in the 
presence or absence ofKu. Immunoblotfing was carried out with DPK1 
antibody. (B) Cleavage of purified Ku70 and Ku80 by granzyme B. (C) 
Cleavage of purified DNA-PKcs by granzyme B and CPP32 and com- 
parison with degradation of DNA-PKcs in cells undergoing apoptosis. 
Fragments were detected by immunoblotting using Ab-FLA antibody 
that recognizes the whole of DNA-PKcs. Lane 1, purified DNA-PKcs. 
Lane 2, DNA-PKcs (0.2 l.tg) incubated fur 2 h with granzyme B (10 ng) 
in the presence of Ku and DNA. Lane 3, extract prepared from clone 
13 incubated with specific peptide for 3 h. Lane 4, extract prepared 
from Burkitt's lymphoma cells exposed to etoposide (68 raM) for 3 h, 
Lane 5, purified DNA-PKcs ((I,2 ~tg) incubated with CPP32 (2 I.tl of 
bacterial lysate) for20 rain in the presence of Ku and DNA. (D) Time 
course of cleavage of purified DNA-PKcs by granzyme B in the pres- 
ence of Ku and comparison with degradation of purified DNA-PKcs by CPP32 in the presence ofKu. hmnunoblotting was carried out with Ab-FLA 
antibody. Lanes 1-6, purified I)NA-PKcs (0.2 p,g) incubated with granzyme B (10 ng) in the presence of Ku and DNA for 0, 0.5, 1, 1.5, 2, 3 h. Lane 7, 
I)NA-PKcs (0.2 I.tg) incubated with CPP32 (2 Ixl of bacterial lysate) for 20 rain in the presence of Ku and DNA. (E) Effect of different doses ofgranzyme 
B on cleavage of purified DNA-PKcs in the presence of Ku after 2 h incubation and comparison with degradation of purified DNA-PKcs by CPP32 in 
the presence ofKu. hnnmnoblotting was carried out with Ab-FLA antibody. Lanes 1-6, purified 1)NA-PKcs (0.2 I, tg) incubated with granzyme B at 0, 
1.25, 2.5, 5, lf), and 20 ng for 2 h in the presence of Ku and DNA. Lane 7, DNA-PKcs ((I.2 ~g} incubated with CPP32 (2 I~1 of bacterial lysate) for 20 
rain in the presence of Ku and DNA. 
tracts demonstrated that cleavage occurred at the same 
DEVDSN site, provid ing further support for the direct in- 
vo lvement  o f  an ICE- l ike protease in DNA-PKcs  degrada- 
tion during T cell killing. 
In the present study we have demonstrated for the first 
t ime that DNA-PKcs  is an important substrate in CTL -  
mediated cytolysis and its cleavage in this intact cell system 
is exclusively due to an ICE- l ike protease. A l though both 
the catalytic and regulatory' subunits o f  DNA-PK  are cleaved 
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by granzyme B in vitro, this enzyme is not a physiological 
substrate for granzyme B. Direct  cleavage of  DNA-PKcs  is 
mediated by an ICE- l ike protease, and granzyme B, which 
plays a major role in CTL  killing, appears to be involved 
upstream from this protease. Recent  studies suggest hat this 
is the case. Darmon et al. (12) demonstrated that granzyme 
B cleaved in vitro translated CPP32, and the cleaved prod- 
uct was active and capable o f  cleaving PARP an important 
substrate in apoptosis. Proteolytic activation o f  CPP32 by 
Figure 4. Effect ofinhibitors on degradation f purified DNA-PKcs by 
extracts prepared from CTL clone LC13 undergoing apoptosis induced 
with specific peptide epitope. Cell extracts were prepared from CTL 
clone LC13 cells treated with specific peptide, 4 h post-treatment, lmmu- 
noblotting was carried out with DPK1 antibody. 
granzyme B was also demonstrated by Quan et al. (13). In 
addition, the Nedd2 precursor can be processed by purified 
granzyme B (Harvey, N.L., J.A. Trapani, and S. Kumar, 
unpublished observation). CPP32 has been shown to 
cleave PARP (21-24), and DNA-PKcs represents only the 
second substrate for this enzyme described here in CTL-  
killing and during apoptosis in Burkitt's lymphoma cells 
treated with etoposide (32). Since both of these enzymes 
are implicated in DNA repair (43-50) their loss would fa- 
cilitate the onset of DNA fragmentation and apoptosis. 
However, since PARP knockout nfice (51) and SCID 
mice (lacking active DNA-PKcs) are able to develop essen- 
tially normally it seems likely that these proteins are not the 
only targets during apoptosis. Indeed, other substrates such 
as nuclear lamin, fodrin, actin, and the U1-70-kD protein 
are cleaved uring apoptosis (26-30). As suggested by Mar- 
tin and Green (52) "too many cuts in too many places re- 
sult in a critical change in the cell and it suddenly collapses 
into apoptotic death." All of  these data point to the impor- 
tance of several critical targets, not all of which are required 
to be degraded in response to a single apoptotic stimulus. 
We have shown that, in CTL killing, activation of  an ICE- 
like protease by granzyme B or another serine protease 
leads to the degradation of  one such critical substrate 
(DNA-PKcs). Clearly, it is important to identify other sub- 
strates involved in this form o fT  cell killing in order to un- 
derstand the nature of the pathway(s) involved. 
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